Novel mechanism of a CDH1 splicing mutation in a Korean patient with signet ring cell carcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
We report a novel mechanism of a CDH1 splicing mutation in a patient with signet ring cell carcinoma of the stomach. A 27-year-old man complaining of aggravated dyspepsia was diagnosed with signet ring cell carcinoma. Both his father and uncle had died of stomach cancer at a young age. DNA sequencing analysis of the CDH1 gene revealed a splice site mutation (c.833-2A＞G). By RNA/cDNA sequencing analysis, CDH1c.833-2A＞G generated a new acceptor site within intron 6, causing the insertion of a 79-bp intronic sequence between exon 6 and 7 (r.833-79_833-1ins), and resulting in a frame shift. E-cadherin immunohistochemical staining revealed a loss of CDH1 expression. This study reveals the disease-causing mechanism of this splicing mutation, and emphasizes the need for functional studies using RNA samples for the accurate interpretation of detected splicing variant. This is the first reported case of a CDH1 mutation in a Korean patient. [BMB reports 2011; 44(11): 725-729]
Abstract
We report a novel mechanism of a CDH1 splicing mutation in a patient with signet ring cell carcinoma of the stomach. A 27-year-old man complaining of aggravated dyspepsia was diagnosed with signet ring cell carcinoma. Both his father and uncle had died of stomach cancer at a young age. DNA sequencing analysis of the CDH1 gene revealed a splice site mutation (c.833-2A＞G). By RNA/cDNA sequencing analysis, CDH1c.833-2A＞G generated a new acceptor site within intron 6, causing the insertion of a 79-bp intronic sequence between exon 6 and 7 (r.833-79_833-1ins), and resulting in a frame shift. E-cadherin immunohistochemical staining revealed a loss of CDH1 expression. This study reveals the disease-causing mechanism of this splicing mutation, and emphasizes the need for functional studies using RNA samples for the accurate interpretation of detected splicing variant. This is the first reported case of a CDH1 mutation in a Korean patient. [BMB reports 2011; 44(11): 725-729]
참고문헌 (12)
- Brooks-Wilson, A. R, "Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria", J. Med. Genet, 41, pp.508~517 (2004)
- Ziogas, D, "CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer", Ann. Surg. Oncol, 16, pp.2678~2681 (2009)
- Graziano, F, "The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice", Ann. Oncol, 14, pp.1705~1713 (2003)
- Humar, B, "Hereditary diffuse gastric cancer: a manifestation of lost cell polarity", Cancer Sci, 100, pp.1151~1157 (2009)
- American Joint Committee in Cancer, "AJCC Cancer Staging Manual. 6th ed" (2002), Springer
- Yoon, K. A, "Germline mutations of E-cadherin gene in Korean familial gastric cancer patients", J. Hum. Genet, 44, pp.177~180 (1999)
- Kim, I. J, "A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome", J. Hum. Genet, 49, pp.591~595 (2004)
- Dicken, B. J, "Gastric adenocarcinoma: review and considerations for future directions", Ann. Surg, 241, pp.27~39 (2005)
- Rogers, W. M, "Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications", Am. J. Surg. Pathol, 32, pp.799~809 (2008)
- Houdayer, C, "Evaluation of in silico splice tools for decision-making in molecular diagnosis", Hum. Mutat, 29, pp.975~982 (2008)
- Pharoah, P. D, "Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families", Gastroenterology, 121, pp.1348~1353 (2001)
- Caldas, C, "Familial gastric cancer: overview and guidelines for management", J. Med. Genet, 36, pp.873~880 (1999)